What is the appropriate workup and treatment for a patient with acanthosis nigricans?

Acanthosis Nigricans: Workup and Treatment

For a patient with acanthosis nigricans, immediately assess for insulin resistance and obesity as the primary underlying causes, then initiate treatment targeting the underlying metabolic condition while considering topical tretinoin for cosmetic improvement of the skin lesions.

Clinical Recognition and Diagnosis

The diagnosis of acanthosis nigricans is primarily clinical, based on characteristic symmetric, hyperpigmented, velvety plaques with ill-defined borders in intertriginous areas such as the neck, axilla, and groin 1, 2, 3. The skin examination should specifically look for these thickened, dark patches in skin folds and creases 1.

Essential Workup

Metabolic Screening (Priority)

The workup must focus on identifying insulin resistance and associated metabolic conditions, as these are the most common underlying causes:

• Fasting glucose and hemoglobin A1C to screen for diabetes and prediabetes 4, 5
• HOMA-IR (Homeostasis Model Assessment-Insulin Resistance) is a good tool for assessment of insulin resistance 5
• Lipid profile including total, LDL, HDL cholesterol and triglycerides 1
• Liver function tests to assess for nonalcoholic fatty liver disease 1
• BMI calculation and assessment for obesity 3, 4

Additional Considerations Based on Clinical Context

• Thyroid-stimulating hormone if clinical suspicion for endocrinopathy 1
• Medication review to identify drug-induced causes 3, 5
• Family history of diabetes, obesity, or metabolic syndrome 3, 4
• Assessment for acanthosis nigricans in unusual locations or atypical morphology may require biopsy to exclude malignancy, though malignancy-associated AN is rare 3, 6

Pediatric-Specific Screening

In children and adolescents with acanthosis nigricans and family history of type 2 diabetes or signs of metabolic disorders, assess fasting glucose even at relatively young ages 1. Screen for associated conditions including polycystic ovary syndrome, mental health issues (anxiety, depression, poor body image), and social functioning 1.

Treatment Algorithm

Step 1: Address Underlying Cause (Primary Treatment)

Weight reduction is the most scientific and practical management strategy 5. This takes absolute priority:

• For obesity-associated AN: Lifestyle modifications including dietary changes and increased physical activity are essential 2, 3, 4
• For insulin resistance/prediabetes: Insulin sensitizers such as metformin may be considered 5
• For medication-induced AN: Discontinue causative drugs if possible 3
• For endocrinopathy-associated AN: Treat the underlying hormonal disorder 3

Step 2: Skin-Directed Therapy

For cosmetic improvement or when underlying cause is not amenable to treatment:

First-Line Topical Treatment (Grade A Evidence)

• Topical tretinoin is strongly recommended as first-line therapy 7
• Limitation: skin irritation is the main adverse effect 8

Alternative Topical Options (Grade B Evidence)

• Adapalene gel 7
• Urea cream 7
• Topical retinoids (general category) for localized lesions 3
• Vitamin D analogs 3
• Alpha hydroxy acids to reduce plaque thickness 2
• Keratolytic agents including salicylic acid 3, 5

Combination Approaches

Combination therapies are increasingly used to combat skin irritation from retinoids alone 8. Consider combining retinoids with moisturizers or other agents to improve tolerability 8.

Step 3: Advanced Interventions for Refractory Cases

For extensive or generalized AN unresponsive to topical therapy:

• Oral retinoids may be considered systemically 3, 5
• Chemical peels with trichloroacetic acid 5
• Fractional carbon dioxide laser therapy (Grade B recommendation) 7
• Long-pulsed alexandrite laser 5
• Fractional 1550-nm erbium fiber laser 5

Step 4: Uncommon Modalities

• Dermabrasion 3
• Surgical removal (rarely indicated) 3

Critical Pitfalls and Caveats

Common Mistakes to Avoid

1. Treating skin lesions without addressing underlying metabolic disease - This approach fails to prevent disease progression and cardiovascular complications 4

2. Missing malignancy-associated AN - While rare, AN can be a paraneoplastic manifestation. Consider malignancy workup if: lesions appear suddenly, progress rapidly, occur in unusual locations, or patient has atypical demographics 3, 6

3. Inadequate screening in high-risk populations - AN prevalence is significantly elevated in certain groups (e.g., 4.55% in transmasculine patients vs 0.3% general population) 9. Hispanic ethnicity shows increased association 9

4. Expecting complete cure - Complete disappearance of lesions is difficult to achieve even with treatment 3, 5. Set realistic expectations with patients.

5. Overlooking psychological impact - AN negatively affects psychological well-being and particularly impacts individuals with skin of color 7. Address cosmetic concerns and mental health.

Special Populations

Immunosuppressed patients and organ transplant recipients may develop AN and require specialized management 1. These patients warrant closer monitoring for progression to malignancy.

Pediatric patients require assessment using staging systems like EOSS-P to evaluate metabolic, biomechanical, mental health, and social domains 1. Early identification enables intervention to prevent long-term cardiovascular consequences 4.

Prognosis and Follow-up

AN is treatable but rarely cures completely 5. The underlying cause must be treated to resolve and prevent recurrence 3. Regular monitoring is essential, particularly for metabolic parameters in patients with insulin resistance 4. Early recognition and treatment of associated comorbidities can lead to improved health outcomes 9.